Protective Effects of Dabrafenib on Doxorubicin-Induced Cardiotoxicity in Rats
Open Access
Abstract
Doxorubicin (DOX) is a commonly used antineoplastic agent whose clinical use is mainly limited by its cardiotoxicity. Since necroptosis has been implicated in DOX-induced cardiotoxicity, this study investigated and compared the protective effects of dabrafenib (Dab), a RIPK3 inhibitor, and necrostatin-1 (Nec-1), a RIPK1 inhibitor, targeting two key components of the necroptotic signaling pathway. Thirty-six male Sprague–Dawley rats were divided into four groups: control, DOX, DOX+Dab, and DOX+Nec-1. Coronary perfusion pressure was assessed in isolated hearts using the Langendorff system, while serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels, cardiac malondialdehyde (MDA) levels, histopathological alterations, and the expression of necroptosis-related proteins were analyzed. DOX treatment significantly increased coronary perfusion pressure, serum CK and LDH levels, cardiac MDA levels, and RIPK1, RIPK3, and mixed lineage kinase domain-like protein (MLKL) expression and induced marked histopathological damage. Both dabrafenib and Nec-1 attenuated these alterations and histopathological damage, although the magnitude of their effects varied across the measured outcomes. No significant differences in serum CK or LDH levels were observed between the two treatment groups. Overall, our findings suggest that dabrafenib may attenuate DOX-induced cardiac injury, although its effects on necroptotic signaling remain to be established.Keywords
Funding Information
- Dicle University (TIP.20.019)
- Dicle University (ECZACILIK.26.016)
This publication has 40 references indexed in Scilit:
- 6‐Shogaol Attenuates Doxorubicin‐Induced Cardiac and Skeletal Muscle Atrophy by Inhibiting E3 Ubiquitin Ligases and NecroptosisPhytotherapy Research, 2026
- Managing Doxorubicin Cardiotoxicity: Insights Into Molecular Mechanisms and Protective StrategiesJournal of Biochemical and Molecular Toxicology, 2025
- The mechanism and therapeutic strategies in doxorubicin-induced cardiotoxicity: Role of programmed cell deathCell Stress and Chaperones, 2024
- An in vitro evaluation of the antioxidant activities of necroptosis and apoptosis inhibitors: the potential of necrostatin-1 and necrostatin-1i to have radical scavenging activitiesPharmacological Reports, 2023
- Doxorubicin induced cardio toxicity through sirtuins mediated mitochondrial disruptionChemico-Biological Interactions, 2022
- Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic ApproachesCardiovascular Toxicology, 2022
- Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registriesCancer Medicine, 2021
- Cardiovascular Adverse Events Associated With BRAF and MEK InhibitorsJAMA Network Open, 2019
- Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia–reperfusion in vivoBasic Research in Cardiology, 2012
- Measurement of lipid peroxidation in vivo: A comparison of different proceduresLipids, 1987